The company's principal activity is to develop and market pharmaceutical products for the treatment of autoimmune and other cell-mediated inflammatory diseases. The products are based on the principles of mucosal tolerance. Mucosal tolerance utilizes the natural immune system mechanisms associated with the gut, nasal passages, lungs and other mucosally lined tissues. The products consist of drugs for the treatment of rheumatoid arthritis, type 1 diabetes and multiple sclerosis. The company operates in the United States of America and is in its development stage.
